GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Steve Cohen Bets On Orexigen Ahead of FDA Approval

January 31, 2011 | About:
matsandalex

matsandalex

10 followers
Steve Cohen, manager of the SAC Capital hedge fund, revealed a stake in Orexigen Therapeutics (OREX) in the latest 13G filing. The fund revealed a 2.37 million stake ahead of an FDA decision on an obesity drug called Contrave.

Although the $20+ million stake is not significant for a multi-billion dollar hedge fund, the move raised eyebrows on Wall Street. OREX is not one of the fund's top ten holdings. However, OREX only has a market cap of $430 million making SAC Capital one of the largest shareholders.

More importantly, investors are betting that Cohen's stake means that his firm believes that Orexigen's drug will be approved by the FDA. The FDA decision that was due today but was delayed.

The stock rose 9.3% today in response to either the filing or the expectation that the obesity drug will be approved by the FDA.

Orexigen has two obesity drugs in the pipeline including Contrave, which has completed Phase III clinical trials; and Empatic that has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR).



Rating: 4.1/5 (15 votes)

Comments

SharadDhingra
SharadDhingra - 3 years ago


SAC got smoked unless they threw a bunch of $5 puts up against this.

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK